In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Bio-Rad gets new DNA sequencing offering with GnuBIO buy

This article was originally published in Clinica

Executive Summary

Life sciences research and clinical diagnostic specialist Bio-Rad Laboratories has moved into the DNA sequencing sector, purchasing GnuBIO for an undisclosed fee. The privately-held Cambridge, Massachusetts firm has developed a “faster and fully integrated” droplet-based sequencing technology that produces results in a few hours instead of days, according to the company, and can be used in medical diagnostics as well as research markets. According to GnuBIO’s website: “Whereas other sequencing technologies require separate workflows for target selection, DNA amplification, DNA sequencing and analysis, the GnuBIO technology integrates the entire workflow into a single, low-cost instrument.” Jefferies analyst Brandon Couillard said he was "disappointed to see another early-stage dilutive acquisition," estimating that it would hit Bio-Rad to the tune of around $20m per year. However, the analyst added: "While Bio-Rad's foray into next-generation sequencing makes us somewhat skittish, [it] is clearly investing for future market developments and its stellar acquisition track record has earned it the benefit of the doubt here." He concluded: "We expect Bio-Rad to bring significant technical & commercial know-how to GnuBIO, owing to its well-established presence in droplet digital PCR with QuantaLife."






Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts